أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - lidocaine, quantity: 20 mg/ml; chlorhexidine gluconate, quantity: 0.5 mg/ml - gel - excipient ingredients: glacial acetic acid; water for injections; sodium hydroxide; propylene glycol; hyetellose; acetic acid - for local anaesthesia and lubrication of the urethra prior to catheterization. cystoscopy and symptomatic treatment of painful cystisis and urethritis.

نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - varenicline tartrate 0.85mg equivalent to 0.5 mg varenicline;  ;   - film coated tablet - 0.5 mg - active: varenicline tartrate 0.85mg equivalent to 0.5 mg varenicline     excipient: calcium hydrogen phosphate colloidal silicon dioxide croscarmellose sodium magnesium stearate microcrystalline cellulose opadry clear ys-2-19114-a opadry white ys-1-18202 - an aid to smoking cessation

نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - varenicline tartrate 1.71mg equivalent to 1 mg varenicline;  ;   - film coated tablet - 1 mg - active: varenicline tartrate 1.71mg equivalent to 1 mg varenicline     excipient: calcium hydrogen phosphate colloidal silicon dioxide croscarmellose sodium magnesium stearate microcrystalline cellulose opadry blue 03b90547 opadry clear ys-2-19114-a - an aid to smoking cessation

نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - varenicline tartrate 0.85mg equivalent to 0.5 mg varenicline;  ;  ; varenicline tartrate 1.71mg equivalent to 1 mg varenicline - combination - 0.5 mg and 1 mg - active: varenicline tartrate 0.85mg equivalent to 0.5 mg varenicline     excipient: calcium hydrogen phosphate colloidal silicon dioxide croscarmellose sodium magnesium stearate microcrystalline cellulose opadry clear ys-2-19114-a opadry white ys-1-18202 active: varenicline tartrate 1.71mg equivalent to 1 mg varenicline excipient: calcium hydrogen phosphate colloidal silicon dioxide croscarmellose sodium magnesium stearate microcrystalline cellulose opadry blue 03b90547 opadry clear ys-2-19114-a - an aid to smoking cessation

إسرائيل - الإنجليزية - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - azithromycin as dihydrate - powder for solution for infusion - azithromycin as dihydrate 500 mg/vial - azithromycin - azithromycin - treatment of infections caused by susceptible strains of the designated microorganisms in the following conditions: community-acquired pneumonia and pelvic inflammatory disease.

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - bupivacaine hydrochloride monohydrate, quantity: 52.8 mg - injection, solution - excipient ingredients: water for injections; sodium chloride; hydrochloric acid; sodium hydroxide - bupivacaine injection is indicated for the production of local or regional anaesthesia and analgesia in individuals as follows: surgical anaesthesia - epidural block for surgery - field block (minor and major nerve blocks and infiltration). analgesia - continuous epidural infusion or intermittent bolus epidural administration for analgesia in post operative pain or labour pain. - field block (minor nerve block amd infiltration). the choice of 2 strengths, 0.25% and 0.5%, makes it possible to vary the degree of motor blockade.

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - midazolam, quantity: 1 mg/ml - injection, solution - excipient ingredients: hydrochloric acid; sodium hydroxide; sodium chloride; water for injections - intravenously as an agent for: conscious sedation prior to short surgical, diagnostic, therapeutic or endoscopic procedures such as bronchoscopy, gastroscopy, cystoscopy,coronary angiography and cardiac catheterisation, either alone or in conjunction with an opioid. induction of anaesthesia preliminary to administration of other anaesthetic agents. with the use of an opioid premedicant, induction of anaesthesia can be obtained with a narrower dose range and in a shorter period of time. intermittent intravenous administration or continuous infusion for: sedation in intensive care units. intramuscularly for: preoperative sedation (induction of sleepiness or drowsiness and relief of apprehension) and to impair memory of perioperative events.

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - midazolam, quantity: 5 mg/ml - injection, solution - excipient ingredients: sodium chloride; sodium hydroxide; hydrochloric acid; water for injections - intravenously as an agent for: conscious sedation prior to short surgical, diagnostic, therapeutic or endoscopic procedures such as bronchoscopy, gastroscopy, cystoscopy,coronary angiography and cardiac catheterisation, either alone or in conjunction with an opioid. induction of anaesthesia preliminary to administration of other anaesthetic agents. with the use of an opioid premedicant, induction of anaesthesia can be obtained with a narrower dose range and in a shorter period of time. intermittent intravenous administration or continuous infusion for: sedation in intensive care units. intramuscularly for: preoperative sedation (induction of sleepiness or drowsiness and relief of apprehension) and to impair memory of perioperative events.

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - midazolam, quantity: 5 mg/ml - injection, solution - excipient ingredients: sodium chloride; water for injections; sodium hydroxide; hydrochloric acid - intravenously as an agent for: conscious sedation prior to short surgical, diagnostic, therapeutic or endoscopic procedures such as bronchoscopy, gastroscopy, cystoscopy,coronary angiography and cardiac catheterisation, either alone or in conjunction with an opioid. induction of anaesthesia preliminary to administration of other anaesthetic agents. with the use of an opioid premedicant, induction of anaesthesia can be obtained with a narrower dose range and in a shorter period of time. intermittent intravenous administration or continuous infusion for: sedation in intensive care units. intramuscularly for: preoperative sedation (induction of sleepiness or drowsiness and relief of apprehension) and to impair memory of perioperative events.

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - etoposide, quantity: 20 mg/ml - injection, concentrated - excipient ingredients: macrogol 300; citric acid; polysorbate 80; ethanol absolute - indications as at 3 april 1996: etoposide injection is indicated for the following: small cell carcinoma of the lung. acute monocytic and myelomonocytic leukaemia. hodgkin's disease. non-hodgkin's lymphoma